UNSPSC 51152073: Tolperisone hydrochloride

This classification denotes a muscle relaxant with the molecular structure C16H23NO.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8Z075K2TIG chemically known as 2,4'-dimethyl-3-piperidinopropiophenone hydrochloride, but more commonly known as tolperisone hydrochloride, which bears US NIH Compound Identifier 92965. European Medicines Agency schedules Tolperisone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04912MIG.

Most nations, for tariff and trade purposes, schedule tolperisone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, TOLPERISONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tolperisone hydrochloride bears US NLM identifiers UMLS ID C1564420 and NCI Concept Code C84220. SMILES: CC1CCC(CC1)C(=O)C(C)CN2CCCCC2.CL.

UNSPSC 51152073 Tolperisone hydrochloride is a Commodity code that nominally identifies a specific muscle relaxant pharmaceutical, but recent state and local procurement activity under this code shows substantial mismatch. The single relevant opportunity in the recent record — Seminole County, Florida's IFB for naloxone and drug deactivation systems — involves entirely different products (opioid reversal agents and medication disposal equipment) with no connection to tolperisone. A second tagged opportunity, the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs, addresses pharmacy benefit contracting strategy rather than procurement of any specific drug. The code shows little to no genuine activity aligned with its nominal pharmaceutical scope in current state and local solicitations.

Seminole County represents the only issuing body posting under this code in the recent window, and the opportunity itself (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract included a two-year initial term with optional one-year renewal, required E-Verify compliance and drug-free workplace certification, and was potentially funded through FEMA. The Texas RFI, while tagged to the code, functions as exploratory market intelligence on pharmacy direct-contracting models rather than a purchase of tolperisone or any comparable product. The mismatch between the code's nominal scope and the actual work being solicited suggests either systematic miscoding in the state procurement systems or that this Commodity code sees negligible legitimate activity in current state and local markets.